Bronchoalveolar-Lavage Galactomannan Levels in Invasive Fungal Disease Are Diagnostically Disappointing

In a large, prospective trial involving at-risk patients, this measurement had a sensitivity of 50% and a specificity of 73%.

Although most immunocompromised patients with hematologic malignancies never develop invasive fungal diseases (IFD), the results can be devastating for those who do. The current diagnostic standard for IFD requires either tissue examination or culture. However, less-invasive measures have recently been advocated, including measurement of galactomannan (GM), a component of the cell wall of Aspergillus species, from a bronchoalveolar-lavage (BAL) specimen.

To investigate the diagnostic performance of BAL GM for IFD, researchers conducted a prospective, observational cohort study involving all immunocompromised hematologic patients who underwent diagnostic bronchoscopy at the University Hospital Basel, Switzerland, because of symptoms or signs …

Reviewing Author

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Bronchoalveolar-Lavage Galactomannan Levels in Invasive Fungal Disease Are Diagnostically Disappointing

Topics

Reviewing Author